标准剂量拉替拉韦或依非韦伦方案治疗HIV与结核共感染患者:ANRS 12 300 Reflate TB 2开放标签非劣效随机3期试验
这项多中心开放标签非劣效3期试验纳入460例未接受过抗逆转录病毒治疗且正在接受含利福平抗结核治疗的HIV-1感染者,随机接受拉替拉韦400mg每日两次或依非韦伦600mg每日一次联合替诺福韦和拉米夫定。拉替拉韦耐受性良好,但非劣效性未获证明。
要点
- 在HIV/结核共感染者中,拉替拉韦400mg每日两次相比依非韦伦600mg每日一次未达到非劣效性。
- 拉替拉韦耐受性良好,仅可考虑用于特定患者。
核心结论
- 在正在接受含利福平抗结核治疗的HIV感染者中,拉替拉韦400mg每日两次相比依非韦伦600mg每日一次未达到预设的非劣效性标准。
- 拉替拉韦耐受性良好,可作为部分特定患者的选择。
研究设计与样本
- 多中心、开放标签、非劣效、随机3期试验,在科特迪瓦、巴西、法国、莫桑比克和越南的6个中心开展。
- 纳入460例未接受过抗逆转录病毒治疗的成人HIV-1感染者,且已启动含利福平抗结核治疗不超过8周。
- 按1:1随机分配至拉替拉韦400mg每日两次(n=230)或依非韦伦600mg每日一次(n=230),均联合替诺福韦和拉米夫定。
- 主要终点为48周病毒学抑制(血浆HIV RNA<50拷贝/mL),预设非劣效界值为12%。
主要发现
- 意向治疗人群457例(拉替拉韦组230例,依非韦伦组227例),治疗中人群410例(拉替拉韦组206例,依非韦伦组204例)。
- 最常见不良事件为HIV相关非AIDS疾病(拉替拉韦组8/229[3%],依非韦伦组21/230[9%])和AIDS定义性疾病(拉替拉韦组10/229[4%],依非韦伦组13/230[6%])。
- 3或4级不良事件发生率:拉替拉韦组58/229(25%),依非韦伦组66/230(29%);随访期间死亡26/457(6%),依非韦伦组14例,拉替拉韦组12例。
关键数值与推荐
- 主要终点非劣效界值为12%。
- 48周病毒学抑制定义为血浆HIV RNA<50拷贝/mL。
- 意向治疗人群排除2例HIV-2感染和1例入组时HIV-1 RNA<50拷贝/mL的患者。
临床怎么用
- 对于接受含利福平抗结核治疗的HIV感染者,拉替拉韦400mg每日两次未证明非劣效于依非韦伦600mg每日一次。
- 拉替拉韦耐受性良好,但仅可考虑用于特定患者,临床决策需个体化。
局限性
- 开放标签设计。
- 48周时治疗中人群样本量减少(410/457)。
- 意向治疗人群病毒学抑制率总体不高(61%和66%),可能受基线低CD4和高病毒载量影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients co-infected with HIV and tuberculosis, antiretroviral therapy options are limited due to drug-drug interactions with rifampicin. A previous phase 2 trial indicated that raltegravir 400 mg twice a day or efavirenz 600 mg once a day might have similar virological efficacy in patients given rifampicin. In this phase 3 trial, we assessed the non-inferiority of raltegravir to efavirenz. METHODS: We did a multicentre, open-label, non-inferiority, randomised, phase 3 trial at six sites in Côte d'Ivoire, Brazil, France, Mozambique, and Vietnam. We included antiretroviral therapy (ART)-naive adults (aged ≥18 years) with confirmed HIV-1 infection and bacteriologically confirmed or clinically diagnosed tuberculosis who had initiated rifampicin-containing tuberculosis treatment within the past 8 weeks. Using computerised random numbers, we randomly assigned participants (1:1; stratified by country) to receive raltegravir 400 mg twice daily or efavirenz 600 mg once daily, both in combination with tenofovir and lamivudine. The primary outcome was the proportion of patients with virological suppression at week 48 (defined as plasma HIV RNA concentration <50 copies per mL). The prespecified non-inferiority margin was 12%. The primary outcome was assessed in the intention-to-treat population, which included all randomly assigned patients (excluding two patients with HIV-2 infection and one patient with HIV-1 RNA concentration of <50 copies per mL at inclusion), and the on-treatment population, which included all patients in the intention-to-treat population who initiated treatment and were continuing allocated treatment at week 48, and patients who had discontinued allocated treatment due to death or virological failure. Safety was assessed in all patients who received at least one dose of the assigned treatment regimen. This study is registered with ClinicalTrials.gov, NCT02273765. FINDINGS: Between Sept 28, 2015, and Jan 5, 2018, 460 participants were randomly assigned to raltegravir (n=230) or efavirenz (n=230), of whom 457 patients (230 patients in the raltegravir group; 227 patients in the efavirenz group) were included in the intention-to-treat analysis and 410 (206 patients in the raltegravir group; 204 patients in the efavirenz group) in the on-treatment analysis. At baseline, the median CD4 count was 103 cells per μL and median plasma HIV RNA concentration was 5·5 log10 copies per mL (IQR 5·0-5·8). 310 (68%) of 457 participants had bacteriologically-confirmed tuberculosis. In the intention-to-treat population, at week 48, 140 (61%) of 230 participants in the raltegravir group and 150 (66%) of 227 patients in the efavirenz had achieved virological suppression (between-group difference -5·2% [95% CI -14·0 to 3·6]), thus raltegravir did not meet the predefined criterion for non-inferiority. The most frequent adverse events were HIV-associated non-AIDS illnesses (eight [3%] of 229 patients in the raltegravir group; 21 [9%] of 230 patients in the efavirenz group) and AIDS-defining illnesses (ten [4%] patients in the raltegravir group; 13 [6%] patients in the efavirenz group). 58 (25%) of 229 patients in raltegravir group and 66 (29%) of 230 patients in the efavirenz group had grade 3 or 4 adverse events. 26 (6%) of 457 patients died during follow-up: 14 in the efavirenz group and 12 in the raltegravir group. INTERPRETATION: In patients with HIV given tuberculosis treatment, non-inferiority of raltegravir compared with efavirenz was not shown. Raltegravir was well tolerated and could be considered as an option, but only in selected patients. FUNDING: National French Agency for AIDS Research, Ministry of Health in Brazil, Merck. TRANSLATIONS: For the Portuguese and French translations of the abstract see Supplementary Materials section.
引用
- De Castro N, Marcy O, Chazallon C, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis. 2021. PMID: 33667406. doi:10.1016/S1473-3099(20)30869-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。